132 related articles for article (PubMed ID: 23995645)
1. Functional alterations of intestinal P-glycoprotein under diabetic conditions.
Kobori T; Harada S; Nakamoto K; Tokuyama S
Biol Pharm Bull; 2013; 36(9):1381-90. PubMed ID: 23995645
[TBL] [Abstract][Full Text] [Related]
2. [Altered intestinal P-glycoprotein expression levels affect pharmacodynamics under diabetic condition].
Nawa A; Fujita-Hamabe W; Kisioka S; Tokuyama S
Yakugaku Zasshi; 2012; 132(2):161-6. PubMed ID: 22293693
[TBL] [Abstract][Full Text] [Related]
3. Modulation of expression/function of intestinal P-glycoprotein under disease states.
Murakami T; Bodor E; Bodor N
Expert Opin Drug Metab Toxicol; 2020 Jan; 16(1):59-78. PubMed ID: 31821048
[No Abstract] [Full Text] [Related]
4. Prediction of Atorvastatin Pharmacokinetics in High-Fat Diet and Low-Dose Streptozotocin-Induced Diabetic Rats Using a Semiphysiologically Based Pharmacokinetic Model Involving Both Enzymes and Transporters.
Wang Z; Yang H; Xu J; Zhao K; Chen Y; Liang L; Li P; Chen N; Geng D; Zhang X; Liu X; Liu L
Drug Metab Dispos; 2019 Oct; 47(10):1066-1079. PubMed ID: 31399507
[TBL] [Abstract][Full Text] [Related]
5. Mechanisms of P-glycoprotein alteration during anticancer treatment: role in the pharmacokinetic and pharmacological effects of various substrate drugs.
Kobori T; Harada S; Nakamoto K; Tokuyama S
J Pharmacol Sci; 2014; 125(3):242-54. PubMed ID: 24989947
[TBL] [Abstract][Full Text] [Related]
6. Tetrandrine potentiates the hypoglycemic efficacy of berberine by inhibiting P-glycoprotein function.
Shan YQ; Zhu YP; Pang J; Wang YX; Song DQ; Kong WJ; Jiang JD
Biol Pharm Bull; 2013; 36(10):1562-9. PubMed ID: 23924821
[TBL] [Abstract][Full Text] [Related]
7. Involvement of ubiquitination in the decrease of intestinal P-glycoprotein in a streptozotocin-induced diabetic mouse model.
Nawa A; Fujita-Hamabe W; Tokuyama S
Drug Metab Pharmacokinet; 2012; 27(5):548-52. PubMed ID: 22498644
[TBL] [Abstract][Full Text] [Related]
8. Decreased expression of intestinal P-glycoprotein increases the analgesic effects of oral morphine in a streptozotocin-induced diabetic mouse model.
Nawa A; Fujita-Hamabe W; Kishioka S; Tokuyama S
Drug Metab Pharmacokinet; 2011; 26(6):584-91. PubMed ID: 21878740
[TBL] [Abstract][Full Text] [Related]
9. Changes in the localization of ileal P-glycoprotein induced by intestinal ischemia/reperfusion.
Takizawa Y; Kishimoto H; Kitazato T; Tomita M; Hayashi M
Biol Pharm Bull; 2011; 34(3):408-14. PubMed ID: 21372393
[TBL] [Abstract][Full Text] [Related]
10. Tissue-specific alterations in expression and function of P-glycoprotein in streptozotocin-induced diabetic rats.
Zhang LL; Lu L; Jin S; Jing XY; Yao D; Hu N; Liu L; Duan R; Liu XD; Wang GJ; Xie L
Acta Pharmacol Sin; 2011 Jul; 32(7):956-66. PubMed ID: 21685928
[TBL] [Abstract][Full Text] [Related]
11. Effect of variations in the amounts of P-glycoprotein (ABCB1), BCRP (ABCG2) and CYP3A4 along the human small intestine on PBPK models for predicting intestinal first pass.
Bruyère A; Declèves X; Bouzom F; Ball K; Marques C; Treton X; Pocard M; Valleur P; Bouhnik Y; Panis Y; Scherrmann JM; Mouly S
Mol Pharm; 2010 Oct; 7(5):1596-607. PubMed ID: 20604570
[TBL] [Abstract][Full Text] [Related]
12. Regional difference in intestinal drug absorption as a measure for the potential effect of P-glycoprotein efflux transporters.
Ashmawy SM; El-Gizawy SA; El Maghraby GM; Osman MA
J Pharm Pharmacol; 2019 Mar; 71(3):362-370. PubMed ID: 30362574
[TBL] [Abstract][Full Text] [Related]
13. The pharmacological role of P-glycoprotein in the intestinal epithelium.
Van Asperen J; Van Tellingen O; Beijnen JH
Pharmacol Res; 1998 Jun; 37(6):429-35. PubMed ID: 9695116
[TBL] [Abstract][Full Text] [Related]
14. Alteration of P-gp expression after intestinal ischemia-reperfusion following 16-h fasting in rats.
Ogura J; Fujikawa A; Maruyama H; Kobayashi M; Itagaki S; Iseki K
Yakugaku Zasshi; 2011 Mar; 131(3):453-62. PubMed ID: 21372543
[TBL] [Abstract][Full Text] [Related]
15. Characterization of P-Glycoprotein Humanized Mice Generated by Chromosome Engineering Technology: Its Utility for Prediction of Drug Distribution to the Brain in Humans.
Yamasaki Y; Kobayashi K; Okuya F; Kajitani N; Kazuki K; Abe S; Takehara S; Ito S; Ogata S; Uemura T; Ohtsuki S; Minegishi G; Akita H; Chiba K; Oshimura M; Kazuki Y
Drug Metab Dispos; 2018 Nov; 46(11):1756-1766. PubMed ID: 29777024
[TBL] [Abstract][Full Text] [Related]
16. Unmasking the dynamic interplay between intestinal P-glycoprotein and CYP3A4.
Cummins CL; Jacobsen W; Benet LZ
J Pharmacol Exp Ther; 2002 Mar; 300(3):1036-45. PubMed ID: 11861813
[TBL] [Abstract][Full Text] [Related]
17. Quantitative prediction of intestinal metabolism in humans from a simplified intestinal availability model and empirical scaling factor.
Kadono K; Akabane T; Tabata K; Gato K; Terashita S; Teramura T
Drug Metab Dispos; 2010 Jul; 38(7):1230-7. PubMed ID: 20354105
[TBL] [Abstract][Full Text] [Related]
18. Regulatory action of nitric oxide synthase on ileal P-glycoprotein expression under streptozotocin-induced diabetic condition.
Nawa A; Fujita-Hamabe W; Tokuyama S
Biol Pharm Bull; 2011; 34(3):436-8. PubMed ID: 21372399
[TBL] [Abstract][Full Text] [Related]
19. Intestinal transporters: enhanced absorption through P-glycoprotein-related drug interactions.
Zakeri-Milani P; Valizadeh H
Expert Opin Drug Metab Toxicol; 2014 Jun; 10(6):859-71. PubMed ID: 24708201
[TBL] [Abstract][Full Text] [Related]
20. Drug exsorption from blood into the gastrointestinal tract.
Arimori K; Nakano M
Pharm Res; 1998 Mar; 15(3):371-6. PubMed ID: 9563065
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
